nodes	percent_of_prediction	percent_of_DWPC	metapath
Droperidol—Consciousness abnormal—Vincristine—lymphatic system cancer	0.106	0.106	CcSEcCtD
Droperidol—Sudden death—Teniposide—lymphatic system cancer	0.0671	0.0671	CcSEcCtD
Droperidol—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.053	0.053	CcSEcCtD
Droperidol—Altered state of consciousness—Vincristine—lymphatic system cancer	0.04	0.04	CcSEcCtD
Droperidol—Sudden death—Mitoxantrone—lymphatic system cancer	0.0351	0.0351	CcSEcCtD
Droperidol—Inappropriate antidiuretic hormone secretion—Vincristine—lymphatic system cancer	0.0317	0.0317	CcSEcCtD
Droperidol—Depression—Mechlorethamine—lymphatic system cancer	0.026	0.026	CcSEcCtD
Droperidol—Bronchospasm—Teniposide—lymphatic system cancer	0.0212	0.0212	CcSEcCtD
Droperidol—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.0204	0.0204	CcSEcCtD
Droperidol—Sudden death—Methotrexate—lymphatic system cancer	0.0175	0.0175	CcSEcCtD
Droperidol—Gynaecomastia—Carmustine—lymphatic system cancer	0.0173	0.0173	CcSEcCtD
Droperidol—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.0171	0.0171	CcSEcCtD
Droperidol—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0166	0.0166	CcSEcCtD
Droperidol—Chills—Teniposide—lymphatic system cancer	0.0155	0.0155	CcSEcCtD
Droperidol—Bronchospasm—Bleomycin—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Droperidol—Chills—Fludarabine—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Droperidol—Hypertension—Teniposide—lymphatic system cancer	0.013	0.013	CcSEcCtD
Droperidol—Cardiac arrest—Vincristine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Droperidol—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Droperidol—Tachycardia—Teniposide—lymphatic system cancer	0.012	0.012	CcSEcCtD
Droperidol—Hypotension—Teniposide—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Droperidol—Hyperglycaemia—Carmustine—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Droperidol—Depression—Carmustine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Droperidol—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Droperidol—Rash—Mechlorethamine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Droperidol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Droperidol—Depression—Vincristine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Droperidol—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Droperidol—Drowsiness—Mitoxantrone—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Droperidol—Chills—Bleomycin—lymphatic system cancer	0.00998	0.00998	CcSEcCtD
Droperidol—Body temperature increased—Teniposide—lymphatic system cancer	0.00969	0.00969	CcSEcCtD
Droperidol—Hallucination—Carmustine—lymphatic system cancer	0.00966	0.00966	CcSEcCtD
Droperidol—Hallucination—Vincristine—lymphatic system cancer	0.00922	0.00922	CcSEcCtD
Droperidol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00903	0.00903	CcSEcCtD
Droperidol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00852	0.00852	CcSEcCtD
Droperidol—Chills—Mitoxantrone—lymphatic system cancer	0.0081	0.0081	CcSEcCtD
Droperidol—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00801	0.00801	CcSEcCtD
Droperidol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00794	0.00794	CcSEcCtD
Droperidol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0079	0.0079	CcSEcCtD
Droperidol—Rash—Teniposide—lymphatic system cancer	0.00773	0.00773	CcSEcCtD
Droperidol—Dermatitis—Teniposide—lymphatic system cancer	0.00772	0.00772	CcSEcCtD
Droperidol—Hypotension—Bleomycin—lymphatic system cancer	0.00738	0.00738	CcSEcCtD
Droperidol—Hypertension—Carmustine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Droperidol—Anxiety—Carmustine—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Droperidol—Hypertension—Vincristine—lymphatic system cancer	0.00696	0.00696	CcSEcCtD
Droperidol—Rash—Fludarabine—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Droperidol—Dermatitis—Fludarabine—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Droperidol—Hypertension—Mitoxantrone—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Droperidol—Tachycardia—Carmustine—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Droperidol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00666	0.00666	CcSEcCtD
Droperidol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Droperidol—Hypotension—Carmustine—lymphatic system cancer	0.00644	0.00644	CcSEcCtD
Droperidol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00641	0.00641	CcSEcCtD
Droperidol—Shock—Mitoxantrone—lymphatic system cancer	0.00631	0.00631	CcSEcCtD
Droperidol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Droperidol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Droperidol—Hypotension—Vincristine—lymphatic system cancer	0.00615	0.00615	CcSEcCtD
Droperidol—Somnolence—Carmustine—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Droperidol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Droperidol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Droperidol—Somnolence—Mitoxantrone—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Droperidol—Body temperature increased—Carmustine—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Droperidol—Body temperature increased—Vincristine—lymphatic system cancer	0.0052	0.0052	CcSEcCtD
Droperidol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00508	0.00508	CcSEcCtD
Droperidol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Droperidol—Drowsiness—Methotrexate—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Droperidol—Depression—Methotrexate—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Droperidol—Rash—Bleomycin—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Droperidol—Dermatitis—Bleomycin—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Droperidol—Hypersensitivity—Vincristine—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Droperidol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Droperidol—Dizziness—Carmustine—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Droperidol—Dizziness—Vincristine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Droperidol—Rash—Carmustine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Droperidol—Dermatitis—Carmustine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Droperidol—Rash—Vincristine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Droperidol—Dermatitis—Vincristine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Droperidol—Rash—Mitoxantrone—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Droperidol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Droperidol—Chills—Methotrexate—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Droperidol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Droperidol—Hypotension—Methotrexate—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Droperidol—Somnolence—Methotrexate—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Droperidol—Body temperature increased—Methotrexate—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Droperidol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Droperidol—Dizziness—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Droperidol—Rash—Methotrexate—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Droperidol—Dermatitis—Methotrexate—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
